Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors
- 20 December 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (36) , 9290-9294
Abstract
Purpose: To assess response, overall survival, and relapse-free survival of patients with good-risk metastatic germ cell tumor (GCT) by International Germ Cell Consensus Classification Group (IGCCCG) criteria treated with four cycles of etoposide and cisplatin (EP). Patients and Methods: Two hundred eighty-nine patients with IGCCCG good-risk GCT were treated with four cycles of EP. EP consisted of four cycles of etoposide 100 mg/m2 and cisplatin 20 mg/m2 on days 1 to 5 every 21 days. Results: Two hundred eighty-two of 289 patients (98%) achieved a complete response; 269 (93%) responded to chemotherapy alone and 13 (5%) responded to chemotherapy plus surgical resection of viable disease (GCT other than mature teratoma). Seventeen (6%) experienced relapse, and nine (3%) died as a result of disease at a median follow-up of 7.7 years (range, 0.4 to 21.1 years). Sixty-two of 204 patients (30%) with nonseminoma had findings of teratoma or viable GCT at postchemotherapy surgery. Conclusion: Four cycles of EP is a highly effective therapy for patients with good-risk GCT, with a high cure rate, low relapse rate, and little evidence of late relapse. Postchemotherapy surgery resection of residual disease remains an important aspect of treatment for these patients. Four cycles of EP is acceptable as a standard regimen for the treatment of good-risk metastatic GCT, and serves as an alternative to three cycles of bleomycin and etoposide before cisplatin.Keywords
This publication has 12 references indexed in Scilit:
- The role of retroperitoneal lymph node dissection in the management of testicular cancerUrologic Oncology: Seminars and Original Investigations, 2004
- Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trialThe Lancet, 2001
- Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.Journal of Clinical Oncology, 1997
- Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors.Journal of Clinical Oncology, 1997
- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.Journal of Clinical Oncology, 1997
- Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.Journal of Clinical Oncology, 1990
- A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.Journal of Clinical Oncology, 1988
- VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.Journal of Clinical Oncology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958